Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Completed · Phase 1
Conditions studied: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
In brief
This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). A single infusion of Avastin® is added to standard-of-care high dose steroids and an additional dose of Avastin® is added to plasma exchange (if necessary). The primary outcomes are clinical changes in the Expanded Disability Severity Scale, Timed 25-foot Walk and Low Contrast Visual Acuity, MRI parameters and safety.
Key facts
- Study ID
- NCT01777412
- Run by
- Johns Hopkins University
- People needed
- 10
- Starts
- 2013-06-01
- Expected to finish
- 2015-05-01
- Last updated by the study team
- 2015-08-21
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Johns Hopkins Hospital — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.